Pristiq (Desvenlafaxine)
desvenlafaxine succinate extended-release tablets
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Major Depressive Disorder (MDD) | Adults (18+) | Monotherapy | FDA Approved |
Desvenlafaxine is the active metabolite of venlafaxine and carries a narrower indication profile than its parent compound. While venlafaxine holds approvals for generalized anxiety disorder, social anxiety disorder, and panic disorder, desvenlafaxine is approved exclusively for MDD in adults. Its efficacy was demonstrated across four 8-week, placebo-controlled trials using doses of 50 to 400 mg daily, with 50 mg showing a consistent benefit without additional gains at higher doses (FDA PI). Longer-term relapse prevention has also been established in two maintenance trials.
Vasomotor symptoms (menopausal hot flashes): Randomized controlled trials have shown desvenlafaxine 100-150 mg/day reduces hot flash frequency by 60-67% compared to ~51% with placebo. Not FDA-approved for this indication but supported by several RCTs. Evidence quality: Moderate.
Anxiety symptoms comorbid with MDD: Pooled analyses suggest improvement in anxiety subscale scores in depressed patients; however, desvenlafaxine failed to separate from placebo in a dedicated social anxiety disorder trial. Evidence quality: Low.
Neuropathic pain: Limited case series only; venlafaxine and duloxetine are preferred SNRIs for this indication. Evidence quality: Very low.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| MDD — new diagnosis, standard patient | 50 mg once daily | 50 mg once daily | 400 mg/day | No titration needed; 50 mg is both start and target dose No added efficacy demonstrated above 50 mg; higher doses increase adverse effects (FDA PI) |
| MDD — moderate renal impairment (CrCl 30-50 mL/min) | 50 mg once daily | 50 mg once daily | 50 mg/day | Do not exceed 50 mg/day AUC increased ~56% in moderate renal impairment |
| MDD — severe renal impairment or ESRD (CrCl <30 mL/min) | 25 mg once daily | 25 mg daily or 50 mg every other day | 25 mg/day or 50 mg QOD | Do not give supplemental doses post-dialysis AUC increased ~108% (severe) to ~116% (ESRD) |
| MDD — moderate to severe hepatic impairment (Child-Pugh 7-15) | 50 mg once daily | 50 mg once daily | 100 mg/day | Dose escalation above 100 mg/day is not recommended |
| MDD — switch from venlafaxine | 50 mg once daily | 50 mg once daily | 400 mg/day | Taper venlafaxine gradually to minimize discontinuation symptoms before switching Do not co-administer with venlafaxine |
| MDD — discontinuation / tapering | Reduce to 25 mg daily before stopping | N/A | Taper gradually; some patients may require tapering over weeks to months 25 mg tablet is designed specifically for this purpose | |
| MDD — elderly (65+) | 50 mg once daily | 50 mg once daily | 400 mg/day | No routine age-based adjustment; monitor for orthostatic hypotension Increased orthostatic hypotension risk in patients 65+ |
Unlike venlafaxine, desvenlafaxine does not require dose titration. The recommended starting dose of 50 mg is also the therapeutic dose, which simplifies initiation. The extended-release tablet must be swallowed whole and should not be divided, crushed, chewed, or dissolved. Taking the medication at the same time each day, with or without food, optimizes adherence.
Pharmacology
Mechanism of Action
Desvenlafaxine is the major active metabolite (O-desmethylvenlafaxine) of the antidepressant venlafaxine. It acts as a potent and selective inhibitor of serotonin and norepinephrine reuptake by blocking the serotonin transporter (SERT) and norepinephrine transporter (NET). Desvenlafaxine is approximately 10-fold more potent at inhibiting serotonin reuptake than norepinephrine reuptake. Compared to venlafaxine, desvenlafaxine exhibits more potent noradrenergic effects at lower doses. The dual monoamine reuptake inhibition increases synaptic concentrations of both neurotransmitters in key brain circuits involved in mood regulation, thereby alleviating depressive symptoms. Additionally, by blocking NET in the prefrontal cortex, desvenlafaxine indirectly raises dopamine levels in that region, which may contribute to improvements in concentration and cognitive function associated with depression.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~80% bioavailability; Tmax ~7.5 h (ER formulation); food increases Cmax by ~16% without affecting AUC | Can be given with or without food; steady state achieved in 4-5 days with once-daily dosing |
| Distribution | Vd = 3.4 L/kg; protein binding 30% (concentration-independent) | Wide tissue distribution; low protein binding means minimal displacement interactions with highly bound drugs |
| Metabolism | Primary: UGT conjugation (UGT1A1, UGT1A3, UGT2B4, UGT2B15, UGT2B17); minor: CYP3A4 oxidation | Not significantly affected by CYP2D6 polymorphisms, unlike venlafaxine; low DDI potential via CYP pathway |
| Elimination | t1/2 ~11 h; ~45% excreted unchanged in urine; ~19% as glucuronide metabolite; <5% as oxidative metabolite | Primarily renal elimination; dose reduction required in moderate-severe renal impairment; longer half-life than venlafaxine (~5 h) may reduce discontinuation syndrome risk |
Side Effects
| Adverse Effect | Incidence (50 mg) | Clinical Note |
|---|---|---|
| Nausea | 22% (placebo 10%) | Most common reason for early discontinuation; typically peaks in week 1 and improves by week 2-3; taking with food may help |
| Dizziness | 13% (placebo 5%) | Often orthostatic; advise rising slowly from seated/supine positions; dose-related at higher doses |
| Dry mouth | 11% (placebo 9%) | Encourage oral hygiene, sugar-free gum, and adequate hydration |
| Hyperhidrosis | 10% (placebo 4%) | Dose-related; may be managed with antiperspirants, breathable clothing; rarely requires discontinuation |
| Adverse Effect | Incidence (50 mg) | Clinical Note |
|---|---|---|
| Constipation | 9% (placebo 4%) | Increase dietary fiber and fluid intake; may require osmotic laxative if persistent |
| Insomnia | 9% (placebo 6%) | Consider morning dosing; sleep hygiene education; less prevalent than with venlafaxine |
| Fatigue | 7% (placebo 4%) | Usually improves within 2-4 weeks; distinguish from underlying depressive fatigue |
| Decreased appetite | 5% (placebo 2%) | Monitor weight in underweight patients; mean weight change at 50 mg is -0.4 kg |
| Somnolence | 4% (placebo 4%) | At 50 mg similar to placebo; becomes more prominent at 100 mg (9%) and above |
| Erectile dysfunction (men) | 3% (placebo 1%) | Inquire proactively; lower rates than with SSRIs and venlafaxine in comparative analyses |
| Libido decreased (men) | 4% (placebo 1%) | May persist; discuss management options including dose review or augmentation strategies |
| Blurred vision | 3% (placebo 1%) | Mild and transient in most cases; related to anticholinergic-like effects |
| Anxiety | 3% (placebo 2%) | More common at higher doses; typically transient during first 1-2 weeks |
| Abnormal dreams | 2% (placebo 1%) | Usually not treatment-limiting; may be related to serotonergic effects on REM sleep |
| Mydriasis | 2% (placebo <1%) | Risk factor for angle-closure glaucoma in predisposed patients; screen before initiation |
| Tremor | 2% (placebo 2%) | Fine postural tremor; dose-related (9% at 200 mg); consider dose reduction if bothersome |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Suicidal ideation (age <25) | Uncommon | First weeks of therapy or dose changes | Close monitoring; consider discontinuation if worsening; FDA Black Box Warning |
| Serotonin syndrome | Rare | Hours to days after dose increase or serotonergic co-medication | Discontinue immediately; supportive care; cyproheptadine in severe cases; ICU if hemodynamic instability |
| Sustained hypertension | 1.3% at 50 mg | Weeks to months | Regular BP monitoring; dose reduction or discontinuation if sustained increase |
| Hyponatremia / SIADH | Rare | First weeks; higher risk in elderly | Check serum sodium; discontinue if symptomatic; fluid restriction; endocrine consultation |
| Mania / hypomania activation | ~0.02% | First weeks | Discontinue desvenlafaxine; evaluate for undiagnosed bipolar disorder; initiate mood stabilizer |
| Abnormal bleeding | Uncommon | Any time, especially with concurrent anticoagulants/NSAIDs | Warn patients; monitor for bruising, GI bleeding; adjust anticoagulation as needed |
| Seizures | Rare | Any time | Discontinue; evaluate seizure etiology; avoid in uncontrolled seizure disorders |
| Angle-closure glaucoma | Rare | Any time | Avoid in untreated anatomically narrow angles; urgent ophthalmology referral if acute symptoms |
| Stevens-Johnson syndrome | Very rare (post-marketing) | Variable | Immediate discontinuation; dermatology/burn unit referral; supportive care |
| Interstitial lung disease / eosinophilic pneumonia | Very rare | Variable | Discontinue; chest imaging; pulmonology referral |
| Reason for Discontinuation | Incidence (All Doses) | Context |
|---|---|---|
| Nausea | 4% | Most frequent cause across all dose groups; dose-related |
| Dizziness | 2% | More common at doses above 100 mg |
| Headache | 2% | Usually resolves within first 2 weeks |
| Vomiting | 2% | Also the most common reason in longer-term (9-month) studies |
Nausea is the most clinically relevant tolerability concern with desvenlafaxine, affecting roughly one in five patients at the 50 mg dose. It tends to peak during the first week and resolves for most patients by weeks 2-3. Taking the medication with food, ensuring adequate hydration, and temporarily using short-term antiemetics (e.g., ondansetron) can improve early tolerability. The discontinuation rate at 50 mg due to all adverse events is comparable to placebo (4.1% vs 3.8%), indicating good overall tolerability at the recommended dose.
Drug Interactions
Desvenlafaxine has a notably simple metabolic profile compared to most antidepressants. It is primarily metabolized by UGT conjugation rather than CYP enzymes, does not significantly inhibit or induce CYP1A2, 2A6, 2C8, 2C9, 2C19, 2D6, or 3A4, and is not a substrate or inhibitor of P-glycoprotein. This translates to a low potential for pharmacokinetic drug-drug interactions. However, pharmacodynamic interactions with other serotonergic agents remain clinically important.
Monitoring
-
Blood Pressure
Baseline, then periodically
Routine Pre-existing hypertension should be controlled before initiation. Monitor for sustained BP increases (defined as SDBP ≥90 mmHg and ≥10 mmHg above baseline on 3 consecutive visits). Consider dose reduction or discontinuation if sustained elevation occurs. -
Suicidality Assessment
Weekly for first 4 weeks, then at each visit
Routine Especially important in patients under 25 years. Monitor for clinical worsening, emerging agitation, irritability, akathisia, and suicidal ideation. Also monitor during dose changes and discontinuation. -
Serum Sodium
Baseline; as indicated
Trigger-based Check if symptoms of hyponatremia develop (headache, confusion, weakness, unsteadiness). Elderly patients and those on diuretics are at highest risk. Consider routine periodic monitoring in high-risk populations. -
Renal Function
Baseline
Routine Creatinine clearance determines dosing. Proteinuria (transient, typically benign) has been observed in clinical trials in 6% of patients at 50 mg (vs 4% placebo). -
Lipid Panel
Baseline, then annually
Routine Elevations in total cholesterol, LDL, and triglycerides have been observed in controlled trials. Generally clinically insignificant at 50 mg but more prominent at higher doses. Particularly relevant for patients with baseline dyslipidemia. -
Sexual Function
At initiation, then periodically
Routine Inquire proactively at baseline and follow-up visits, as patients often do not volunteer sexual complaints spontaneously. Includes assessment of erectile function, libido, ejaculatory latency, and orgasm in both sexes. -
Intraocular Pressure
Baseline in at-risk patients
Trigger-based Mydriasis from SNRIs may trigger angle-closure glaucoma in patients with untreated anatomically narrow angles. Ophthalmology evaluation recommended before initiation in at-risk patients. -
Bleeding Signs
Ongoing
Trigger-based Monitor for bruising, epistaxis, GI bleeding, especially in patients taking concurrent anticoagulants, antiplatelet agents, or NSAIDs. Check INR when initiating or stopping desvenlafaxine in warfarin-treated patients.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride, or any excipient in the formulation (angioedema has been reported)
- Concurrent MAOI use or use within 14 days of MAOI discontinuation (risk of fatal serotonin syndrome)
- Initiation in patients receiving linezolid or IV methylene blue (MAO-A inhibition and serotonin syndrome risk)
- Concurrent venlafaxine use (duplication of active moiety)
Relative Contraindications (Specialist Input Recommended)
- Uncontrolled hypertension: Blood pressure must be adequately managed before starting desvenlafaxine; ongoing monitoring is essential
- Severe renal impairment (CrCl <30 mL/min): Dose adjustment required; consider whether an alternative antidepressant with a less renally dependent elimination profile may be preferable
- Untreated narrow-angle glaucoma: Mydriasis induced by desvenlafaxine may precipitate an acute attack; ophthalmology evaluation needed before use
- Active bipolar disorder: Risk of precipitating manic episodes; screening for bipolar disorder recommended before initiation; if used, combine with a mood stabilizer under specialist oversight
Use with Caution
- Seizure disorders: Use cautiously; seizures have been reported rarely
- Hepatic impairment (moderate-severe): Cap dose at 100 mg/day; recommended dose remains 50 mg
- Elderly patients (65+): Higher incidence of orthostatic hypotension (8% vs 0.9% in younger patients); increased SIADH risk
- Patients at risk of bleeding: Concurrent anticoagulant or NSAID use increases bleeding risk through impaired platelet aggregation
- History of mania or hypomania: May activate manic episodes; monitor closely
- Third trimester pregnancy: Neonatal discontinuation syndrome and/or serotonin syndrome-like symptoms reported; weigh risks against untreated maternal depression
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) in short-term studies. Adults over 24 did not show increased risk; adults 65 and older showed reduced risk. Closely monitor all patients for clinical worsening, suicidality, and unusual behavioral changes, especially during the first months of treatment and at dose changes. Desvenlafaxine is not approved for use in pediatric patients.
Desvenlafaxine may cause false-positive urine immunoassay results for phencyclidine (PCP) and amphetamine due to assay cross-reactivity. These false positives may persist for several days after discontinuation. Confirmatory testing with gas chromatography/mass spectrometry will distinguish desvenlafaxine from these substances. Clinicians should inform patients and document this possibility to avoid unnecessary consequences.
Patient Counselling
Purpose of Therapy
Desvenlafaxine is prescribed to treat major depression by restoring the balance of serotonin and norepinephrine in the brain. It may take 2 to 4 weeks before noticeable mood improvement occurs, and full therapeutic benefit may not be apparent for 6 to 8 weeks. Continuing the medication as prescribed is important even after feeling better, as premature discontinuation increases the risk of relapse.
How to Take
Take the tablet once daily at approximately the same time each day, with or without food. Swallow the tablet whole with water; do not split, crush, chew, or dissolve the tablet, as this will compromise the extended-release mechanism. If the patient notices an inert matrix “ghost tablet” in the stool or colostomy, reassure them that the active medication has already been absorbed.
Sources
- Pristiq (desvenlafaxine) Extended-Release Tablets. Full Prescribing Information. Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. Revised June 2024. labeling.pfizer.com Primary source for all dosing, contraindications, adverse reaction incidence rates, and pharmacokinetic parameters cited in this monograph.
- Desvenlafaxine Extended-Release Tablets. FDA-Approved Prescribing Information (Generic). DailyMed/NLM. dailymed.nlm.nih.gov Cross-reference for the most current FDA label including 2023 updates to warnings and precautions.
- DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677-688. doi:10.4088/JCP.v68n0504 Pivotal flexible-dose trial (200-400 mg) establishing efficacy of desvenlafaxine in MDD.
- Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22(6):338-347. Fixed-dose trial supporting 50 mg and 100 mg doses for MDD with HAM-D17 primary endpoint.
- Clayton AH, Tourian KA, Focht K, et al. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015;76(5):562-569. doi:10.4088/JCP.13m08978 Phase 4 trial confirming efficacy of the 50 mg dose and showing no incremental benefit at 100 mg.
- Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Can J Psychiatry. 2024. doi:10.1177/07067437241245384 Current Canadian guideline positioning desvenlafaxine as a first-line antidepressant for MDD.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. APA; 2010. psychiatryonline.org Foundational APA guideline for MDD pharmacotherapy; SNRIs including desvenlafaxine are recommended first-line agents.
- Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657-665. doi:10.1124/jpet.106.103382 Characterizes the pharmacological profile of desvenlafaxine including SERT and NET binding affinities and selectivity ratios.
- DeMaio W, Kane CP, Nichols AI, Jordan R. Metabolism studies of desvenlafaxine. J Bioequiv Availab. 2011;3:151-160. doi:10.4172/jbb.1000076 Comprehensive in vitro and in vivo metabolism study establishing UGT conjugation as the primary metabolic pathway and confirming low CYP-mediated DDI potential.
- Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig. 2011;31(3):155-167. doi:10.2165/11586070-000000000-00000 Demonstrates that CYP2D6 polymorphism status does not clinically affect desvenlafaxine exposure, unlike venlafaxine.
- Sampogna G, Caraci F, Carmassi C, et al. Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and expert opinion. Front Psychiatry. 2023;14:1185596. doi:10.3389/fpsyt.2023.1185596 Real-world evidence review supporting the favorable tolerability and simplified dosing profile of desvenlafaxine 50 mg.
- Redondo-Lobato B, Galeano-Valle F, Calleja-Hernandez MA, et al. Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine. Front Pharmacol. 2023;14:1110460. doi:10.3389/fphar.2023.1110460 Pharmacogenomic analysis across six bioequivalence trials confirming minimal impact of CYP2D6 and UGT polymorphisms on desvenlafaxine PK.